Bafisontamab

巴弗妥单抗

Report date: 2026/02/12 20:00:14

Base Information

Drug NameBafisontamab
Drug Alias NameEMB-01FIT-013a
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptor
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungLung Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Epimab Biotherapeutics, Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEpimab Biotherapeutics IncShanghai Epimab Biotherapeutics, Inc
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungLung Neoplasms +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A